Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Tóm tắt
Từ khóa
Tài liệu tham khảo
Dubois, 2007, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol, 6, 734, 10.1016/S1474-4422(07)70178-3
Jack, 2011, Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, 257, 10.1016/j.jalz.2011.03.004
McKhann, 1984, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939
Varma, 1999, Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia, J Neurol Neurosurg Psychiatry, 66, 184, 10.1136/jnnp.66.2.184
Dubois, 2004, Amnestic MCI or prodromal Alzheimer's disease?, Lancet Neurol, 3, 246, 10.1016/S1474-4422(04)00710-0
Lavenu, 1998, Explicit memory in frontotemporal dementia: the role of medial temporal atrophy, Dement Geriatr Cogn Disord, 9, 99, 10.1159/000017030
Pillon, 1994, Are explicit memory disorders of progressive supranuclear palsy related to damage to striatofrontal circuits? Comparison with Alzheimer's, Parkinson's, and Huntington's diseases, Neurology, 44, 1264, 10.1212/WNL.44.7.1264
Fossati, 2004, Verbal memory performance of patients with a first depressive episode and patients with unipolar and bipolar recurrent depression, J Psychiatr Res, 38, 137, 10.1016/j.jpsychires.2003.08.002
Sarazin, 2010, The amnestic syndrome of hippocampal type in Alzheimer's disease: an MRI study, J Alzheimers Dis, 22, 285, 10.3233/JAD-2010-091150
Dubois, 2010, Revising the definition of Alzheimer's disease: a new lexicon, Lancet Neurol, 9, 1118, 10.1016/S1474-4422(10)70223-4
Morris, 2009, Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease, Arch Neurol, 66, 1469, 10.1001/archneurol.2009.269
Bennett, 2006, Neuropathology of older persons without cognitive impairment from two community-based studies, Neurology, 66, 1837, 10.1212/01.wnl.0000219668.47116.e6
Knopman, 2003, Neuropathology of cognitively normal elderly, J Neuropathol Exp Neurol, 62, 1087, 10.1093/jnen/62.11.1087
Jicha, 2012, Preclinical AD Workgroup staging: pathological correlates and potential challenges, Neurobiol Aging, 33, 622e1, 10.1016/j.neurobiolaging.2011.02.018
Sperling, 2011, Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, 280, 10.1016/j.jalz.2011.03.003
Albert, 2011, The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, 270, 10.1016/j.jalz.2011.03.008
McKhann, 2011, The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, 263, 10.1016/j.jalz.2011.03.005
Prestia, 2013, Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease, Neurology, 80, 1048, 10.1212/WNL.0b013e3182872830
Bouwman, 2010, New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population, Dement Geriatr Cogn Disord, 30, 1, 10.1159/000315542
de Jager, 2010, Retrospective evaluation of revised criteria for the diagnosis of Alzheimer's disease using a cohort with post-mortem diagnosis, Int J Geriatr Psychiatry, 25, 988, 10.1002/gps.2448
Galluzzi, 2010, The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment, J Neurol, 257, 2004, 10.1007/s00415-010-5650-0
Rami, 2012, Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD, Int J Geriatr Psychiatry, 27, 127, 10.1002/gps.2696
Frisoni, 2013, Imaging markers for Alzheimer's disease: which versus how, Neurology, 81, 487, 10.1212/WNL.0b013e31829d86e8
Bateman, 2012, Clinical and biomarker changes in dominantly inherited Alzheimer's disease, N Engl J Med, 367, 795, 10.1056/NEJMoa1202753
Reiman, 2012, Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study, Lancet Neurol, 11, 1048, 10.1016/S1474-4422(12)70228-4
Fleisher, 2012, Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study, Lancet Neurol, 11, 1057, 10.1016/S1474-4422(12)70227-2
Birrer, 2004, Depression in later life: a diagnostic and therapeutic challenge, Am Fam Physician, 69, 2375
Bronnick, 2011, Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited, Neuropsychology, 25, 114, 10.1037/a0020857
Hornberger, 2010, How preserved is episodic memory in behavioral variant frontotemporal dementia?, Neurology, 74, 472, 10.1212/WNL.0b013e3181cef85d
Tounsi, 1999, Sensitivity to semantic cuing: an index of episodic memory dysfunction in early Alzheimer disease, Alzheimer Dis Assoc Disord, 13, 38, 10.1097/00002093-199903000-00006
Sarazin, 2007, Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study, Neurology, 69, 1859, 10.1212/01.wnl.0000279336.36610.f7
Derby, 2013, Screening for predementia AD: time-dependent operating characteristics of episodic memory tests, Neurology, 80, 1307, 10.1212/WNL.0b013e31828ab2c9
Wagner, 2012, Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease, Neurology, 78, 379, 10.1212/WNL.0b013e318245f447
Fortea, 2011, Cognitively preserved subjects with transitional cerebrospinal fluid β-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas, Biol Psychiatry, 70, 183, 10.1016/j.biopsych.2011.02.017
Swerdlow, 2012, Alzheimer disease: can the exam predict the pathology?, Neurology, 78, 374, 10.1212/WNL.0b013e318245f48d
Dubois, 2002, “The 5 words”: a simple and sensitive test for the diagnosis of Alzheimer's disease, Presse Med, 31, 1696
Mura, 2014, Measuring cognitive change in subjects with prodromal Alzheimer's disease, J Neurol Neurosurg Psychiatry, 85, 363, 10.1136/jnnp-2013-305078
Dierckx, 2009, Verbal cued recall as a predictor of conversion to Alzheimer's disease in Mild Cognitive Impairment, Int J Geriatr Psychiatry, 24, 1094, 10.1002/gps.2228
Ahmed, 2008, Predicting rapid clinical progression in amnestic mild cognitive impairment, Dement Geriatr Cogn Disord, 25, 170, 10.1159/000113014
Estevez-Gonzalez, 2003, Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer's disease: comparison with mild cognitive impairment and normal aging, Int J Geriatr Psychiatry, 18, 1021, 10.1002/gps.1010
Fowler, 2002, Paired associate performance in the early detection of DAT, J Int Neuropsychol Soc, 8, 58, 10.1017/S1355617702811067
Landau, 2010, Comparing predictors of conversion and decline in mild cognitive impairment, Neurology, 75, 230, 10.1212/WNL.0b013e3181e8e8b8
Lowndes, 2008, Recall and recognition of verbal paired associates in early Alzheimer's disease, J Int Neuropsychol Soc, 14, 591, 10.1017/S1355617708080806
Ricci, 2012, Using the Rey Auditory Verbal Learning Test (RAVLT) to differentiate Alzheimer's dementia and behavioural variant fronto-temporal dementia, Clin Neuropsychol, 26, 926, 10.1080/13854046.2012.704073
Siri, 2001, A brief neuropsychological assessment for the differential diagnosis between frontotemporal dementia and Alzheimer's disease, Eur J Neurol, 8, 125, 10.1046/j.1468-1331.2001.00179.x
Crane, 2012, Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI), Brain Imaging Behav, 6, 502, 10.1007/s11682-012-9186-z
Barbeau, 2004, Evaluation of visual recognition memory in MCI patients, Neurology, 62, 1317, 10.1212/01.WNL.0000120548.24298.DB
Guedj, 2006, Identification of subgroups in amnestic mild cognitive impairment, Neurology, 67, 356, 10.1212/01.wnl.0000225076.73312.d4
Bird, 2010, Topographical short-term memory differentiates Alzheimer's disease from frontotemporal lobar degeneration, Hippocampus, 20, 1154, 10.1002/hipo.20715
Della Sala, 2012, Short-term memory binding is impaired in AD but not in non-AD dementias, Neuropsychologia, 50, 833, 10.1016/j.neuropsychologia.2012.01.018
Parra, 2010, Visual short-term memory binding deficits in familial Alzheimer's disease, Brain, 133, 2702, 10.1093/brain/awq148
Blennow, 2010, Cerebrospinal fluid and plasma biomarkers in Alzheimer disease, Nat Rev Neurol, 6, 131, 10.1038/nrneurol.2010.4
Buerger, 2006, CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease, Brain, 129, 3035, 10.1093/brain/awl269
Koopman, 2009, Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P), Neurochem Int, 55, 214, 10.1016/j.neuint.2009.02.017
Seppala, 2012, CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings, Neurology, 78, 1568, 10.1212/WNL.0b013e3182563bd0
Strozyk, 2003, CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study, Neurology, 60, 652, 10.1212/01.WNL.0000046581.81650.D0
Tapiola, 2009, Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain, Arch Neurol, 66, 382, 10.1001/archneurol.2008.596
Shaw, 2011, Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI, Acta Neuropathol, 121, 597, 10.1007/s00401-011-0808-0
Le Bastard, 2010, Added diagnostic value of CSF biomarkers in differential dementia diagnosis, Neurobiol Aging, 31, 1867, 10.1016/j.neurobiolaging.2008.10.017
Shaw, 2009, Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects, Ann Neurol, 65, 403, 10.1002/ana.21610
Blennow, 2003, CSF markers for incipient Alzheimer's disease, Lancet Neurol, 2, 605, 10.1016/S1474-4422(03)00530-1
Slaets, 2013, Amyloid pathology influences abeta1-42 cerebrospinal fluid levels in dementia with lewy bodies, J Alzheimers Dis, 35, 137, 10.3233/JAD-122176
Perret-Liaudet, 2012, Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes, J Alzheimers Dis, 31, 13, 10.3233/JAD-2012-120361
Mattsson, 2013, CSF biomarker variability in the Alzheimer's Association quality control program, Alzheimers Dement, 9, 251, 10.1016/j.jalz.2013.01.010
Fagan, 2007, Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults, Arch Neurol, 64, 343, 10.1001/archneur.64.3.noc60123
Hampel, 2004, Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment, Mol Psychiatry, 9, 705, 10.1038/sj.mp.4001473
Hulstaert, 1999, Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF, Neurology, 52, 1555, 10.1212/WNL.52.8.1555
Ibach, 2006, Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample, Neurobiol Aging, 27, 1202, 10.1016/j.neurobiolaging.2005.06.005
Smach, 2009, Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease, Eur Neurol, 62, 349, 10.1159/000241881
Welge, 2009, Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease, J Neural Transm, 116, 203, 10.1007/s00702-008-0177-6
Hansson, 2006, Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol, 5, 228, 10.1016/S1474-4422(06)70355-6
Buchhave, 2012, Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia, Arch Gen Psychiatry, 69, 98, 10.1001/archgenpsychiatry.2011.155
Visser, 2009, Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study, Lancet Neurol, 8, 619, 10.1016/S1474-4422(09)70139-5
Mattsson, 2009, CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment, JAMA, 302, 385, 10.1001/jama.2009.1064
van Rossum, 2010, Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design, J Alzheimers Dis, 20, 881, 10.3233/JAD-2010-091606
Ringman, 2012, Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease, Dement Geriatr Cogn Disord, 33, 1, 10.1159/000335729
Ringman, 2008, Biochemical markers in persons with preclinical familial Alzheimer disease, Neurology, 71, 85, 10.1212/01.wnl.0000303973.71803.81
Bian, 2008, CSF biomarkers in frontotemporal lobar degeneration with known pathology, Neurology, 70, 1827, 10.1212/01.wnl.0000311445.21321.fc
de Souza, 2011, Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias, J Neurol Neurosurg Psychiatry, 82, 240, 10.1136/jnnp.2010.207183
Schoonenboom, 2012, Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort, Neurology, 78, 47, 10.1212/WNL.0b013e31823ed0f0
Brys, 2009, Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment, Neurobiol Aging, 30, 682, 10.1016/j.neurobiolaging.2007.08.010
Li, 2007, CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study, Neurology, 69, 631, 10.1212/01.wnl.0000267428.62582.aa
Snider, 2009, Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type, Arch Neurol, 66, 638, 10.1001/archneurol.2009.55
Verwey, 2009, A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease, Ann Clin Biochem, 46, 235, 10.1258/acb.2009.008232
Fagan, 2011, Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology, Arch Neurol, 68, 1137, 10.1001/archneurol.2011.105
Carrillo, 2013, Research and standardization in Alzheimer's trials: reaching international consensus, Alzheimers Dement, 9, 160, 10.1016/j.jalz.2012.10.006
Hort, 2010, Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe, Eur J Neurol, 17, 90, 10.1111/j.1468-1331.2009.02753.x
Mattsson, 2011, The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers, Alzheimers Dement, 7, 386, 10.1016/j.jalz.2011.05.2243
Joshi, 2012, Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects, J Nucl Med, 53, 378, 10.2967/jnumed.111.090340
Rowe, 2013, Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia, J Nucl Med, 54, 880, 10.2967/jnumed.112.114785
Clark, 2011, Use of florbetapir-PET for imaging beta-amyloid pathology, JAMA, 305, 275, 10.1001/jama.2010.2008
Ikonomovic, 2008, Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease, Brain, 131, 1630, 10.1093/brain/awn016
Leinonen, 2013, Positron emission tomography with [(18) F]flutemetamol and [(11) C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients, Eur J Neurol, 20, 1043, 10.1111/ene.12102
Rinne, 2012, [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid beta detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies, Acta Neuropathol, 124, 833, 10.1007/s00401-012-1051-z
Wolk, 2011, Association between in vivo fluorine 18–labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology, Arch Neurol, 68, 1398, 10.1001/archneurol.2011.153
Forsberg, 2008, PET imaging of amyloid deposition in patients with mild cognitive impairment, Neurobiol Aging, 29, 1456, 10.1016/j.neurobiolaging.2007.03.029
Jack, 2010, Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade, Lancet Neurol, 9, 119, 10.1016/S1474-4422(09)70299-6
Koivunen, 2011, Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study, Neurology, 76, 1085, 10.1212/WNL.0b013e318212015e
Visser, 2009, Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnestic MCI, Neurology, 73, 744, 10.1212/WNL.0b013e3181b61b5d
Herholz, 2011, Clinical amyloid imaging in Alzheimer's disease, Lancet Neurol, 10, 667, 10.1016/S1474-4422(11)70123-5
Aizenstein, 2008, Frequent amyloid deposition without significant cognitive impairment among the elderly, Arch Neurol, 65, 1509, 10.1001/archneur.65.11.1509
Scholl, 2012, Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers, Neurology, 79, 229, 10.1212/WNL.0b013e31825fdf18
Cairns, 2009, Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report, Arch Neurol, 66, 1557, 10.1001/archneurol.2009.279
Okello, 2009, Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study, Neurology, 73, 754, 10.1212/WNL.0b013e3181b23564
Roe, 2013, Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7·5 years later, Neurology, 80, 1784, 10.1212/WNL.0b013e3182918ca6
Fagan, 2006, Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans, Ann Neurol, 59, 512, 10.1002/ana.20730
Forsberg, 2010, High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters, Curr Alzheimer Res, 7, 56, 10.2174/156720510790274446
Grimmer, 2009, Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid, Biol Psychiatry, 65, 927, 10.1016/j.biopsych.2009.01.027
Fagan, 2009, Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease, EMBO Mol Med, 1, 371, 10.1002/emmm.200900048
Jagust, 2009, Relationships between biomarkers in aging and dementia, Neurology, 73, 1193, 10.1212/WNL.0b013e3181bc010c
Tolboom, 2009, Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding, J Nucl Med, 50, 1464, 10.2967/jnumed.109.064360
Galton, 2000, Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases, Brain, 123, 484, 10.1093/brain/123.3.484
Lopez, 1999, Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias, Neurology, 53, 1292, 10.1212/WNL.53.6.1292
Snowden, 2007, Cognitive phenotypes in Alzheimer's disease and genetic risk, Cortex, 43, 835, 10.1016/S0010-9452(08)70683-X
Murray, 2011, Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study, Lancet Neurol, 10, 785, 10.1016/S1474-4422(11)70156-9
Warren, 2012, The paradox of syndromic diversity in Alzheimer disease, Nat Rev Neurol, 8, 451, 10.1038/nrneurol.2012.135
Ross, 1996, Progressive biparietal atrophy: an atypical presentation of Alzheimer's disease, J Neurol Neurosurg Psychiatry, 61, 388, 10.1136/jnnp.61.4.388
Henry, 2010, The logopenic variant of primary progressive aphasia, Curr Opin Neurol, 23, 633, 10.1097/WCO.0b013e32833fb93e
Habek, 2010, Frontal variant of Alzheimer's disease: clinico-CSF-pathological correlation, Can J Neurol Sci, 37, 118, 10.1017/S0317167100009768
Woodward, 2010, Does executive impairment define a frontal variant of Alzheimer's disease?, Int Psychogeriatr, 22, 1280, 10.1017/S1041610210001596
Woodward, 2010, Differentiating the frontal variant of Alzheimer's disease, Int J Geriatr Psychiatry, 25, 732, 10.1002/gps.2415
Alladi, 2007, Focal cortical presentations of Alzheimer's disease, Brain, 130, 2636, 10.1093/brain/awm213
Johnson, 1999, Clinical and pathological evidence for a frontal variant of Alzheimer disease, Arch Neurol, 56, 1233, 10.1001/archneur.56.10.1233
Mendez, 2013, Clinicopathologic differences among patients with behavioral variant frontotemporal dementia, Neurology, 80, 561, 10.1212/WNL.0b013e3182815547
Migliaccio, 2009, Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum, Neurology, 73, 1571, 10.1212/WNL.0b013e3181c0d427
Snowden, 2011, The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships, Brain, 134, 2478, 10.1093/brain/awr189
de Souza, 2011, Similar amyloid-{beta} burden in posterior cortical atrophy and Alzheimer's disease, Brain, 134, 2036, 10.1093/brain/awr130
Leyton, 2011, Subtypes of progressive aphasia: application of the international consensus criteria and validation using {beta}-amyloid imaging, Brain, 134, 3030, 10.1093/brain/awr216
Rosenbloom, 2011, Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution, Neurology, 76, 1789, 10.1212/WNL.0b013e31821cccad
Hof, 1994, Quantitative neuropathologic analysis of Pick's disease cases: cortical distribution of Pick bodies and coexistence with Alzheimer's disease, Acta Neuropathol, 87, 115, 10.1007/BF00296179
Ball, 2010, Theoretical exploration of the neural bases of behavioural disinhibition, apathy and executive dysfunction in preclinical Alzheimer's disease in people with Down's syndrome: potential involvement of multiple frontal-subcortical neuronal circuits, J Intellect Disabil Res, 54, 320, 10.1111/j.1365-2788.2010.01261.x
Jellinger, 2010, Prevalence of dementia disorders in the oldest-old: an autopsy study, Acta Neuropathol, 119, 421, 10.1007/s00401-010-0654-5
Schneider, 2004, Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology, Neurology, 62, 1148, 10.1212/01.WNL.0000118211.78503.F5
Carotenuto, 2012, Late and early onset dementia: what is the role of vascular factors? A retrospective study, J Neurol Sci, 322, 170, 10.1016/j.jns.2012.07.066
McKeith, 2005, Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium, Neurology, 65, 1863, 10.1212/01.wnl.0000187889.17253.b1
McKeith, 2007, Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study, Lancet Neurol, 6, 305, 10.1016/S1474-4422(07)70057-1
Jacova, 2008, Cognitive impairment no dementia – neuropsychological and neuroimaging characterization of an amnestic subgroup, Dement Geriatr Cogn Disord, 2, 238, 10.1159/000115848
Johnson, 2005, Verbal and visuospatial deficits in dementia with Lewy bodies, Neurology, 65, 1232, 10.1212/01.wnl.0000180964.60708.c2
Kraybill, 2005, Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both, Neurology, 64, 2069, 10.1212/01.WNL.0000165987.89198.65
Kandiah, 2009, Differences exist in the cognitive profile of mild Alzheimer's disease and subcortical ischemic vascular dementia, Dement Geriatr Cogn Disord, 27, 399, 10.1159/000210387
Moorhouse, 2010, Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study, J Neurol Sci, 288, 142, 10.1016/j.jns.2009.09.017
Blennow, 2014, Biomarkers in amyloid-beta immunotherapy trials in Alzheimer's disease, Neuropsychopharmacology, 39, 189, 10.1038/npp.2013.154
Pillai, 2013, Clinical trials in predementia stages of Alzheimer disease, Med Clin North Am, 97, 439, 10.1016/j.mcna.2013.01.002
Bateman, 2011, Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease, Alzheimer's Res Ther, 3, 1, 10.1186/alzrt59
Sperling, 2011, Testing the right target and right drug at the right stage, Science Transl Med, 3, 111cm33, 10.1126/scitranslmed.3002609
Rami, 2012, Distinct functional activity of the precuneus and posterior cingulate cortex during encoding in the preclinical stage of Alzheimer's disease, J Alzheimers Dis, 31, 517, 10.3233/JAD-2012-120223
Harold, 2009, Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, Nat Genet, 41, 1088, 10.1038/ng.440
Lambert, 2009, Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease, Nat Genet, 41, 1094, 10.1038/ng.439
Modrego, 2006, Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment, Curr Alzheimer Res, 3, 161, 10.2174/156720506776383103
Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement; Accepted.
Gallassi, 2010, Are subjective cognitive complaints a risk factor for dementia?, Neurol Sci, 31, 327, 10.1007/s10072-010-0224-6
Amariglio, 2012, Subjective cognitive complaints and amyloid burden in cognitively normal older individuals, Neuropsychologia, 50, 2880, 10.1016/j.neuropsychologia.2012.08.011
Mielke, 2012, Indicators of amyloid burden in a population-based study of cognitively normal elderly, Neurology, 79, 1570, 10.1212/WNL.0b013e31826e2696
La Joie, 2012, Region-specific hierarchy between atrophy, hypometabolism, and beta-amyloid (Abeta) load in Alzheimer's disease dementia, J Neurosci, 32, 16265, 10.1523/JNEUROSCI.2170-12.2012
Dickerson, 2012, MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults, Neurology, 78, 84, 10.1212/WNL.0b013e31823efc6c
Magnin, 2009, Support vector machine-based classification of Alzheimer's disease from whole-brain anatomical MRI, Neuroradiology, 51, 73, 10.1007/s00234-008-0463-x
Buckner, 2009, Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease, J Neurosci, 29, 1860, 10.1523/JNEUROSCI.5062-08.2009
Fayed, 2008, Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia, Acad Radiol, 15, 1089, 10.1016/j.acra.2008.04.008
Kantarci, 2003, Neuroimaging in Alzheimer disease: an evidence-based review, Neuroimaging Clin N Am, 13, 197, 10.1016/S1052-5149(03)00025-X
Qi, 2010, Impairment and compensation coexist in amnestic MCI default mode network, Neuroimage, 50, 48, 10.1016/j.neuroimage.2009.12.025
Risacher, 2009, Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort, Curr Alzheimer Res, 6, 347, 10.2174/156720509788929273
Barkhof, 2007, The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old, Neurology, 69, 1521, 10.1212/01.wnl.0000277459.83543.99
Fotuhi, 2012, Modifiable factors that alter the size of the hippocampus with ageing, Nat Rev Neurol, 8, 189, 10.1038/nrneurol.2012.27
de Souza, 2013, Is hippocampal volume a good marker to differentiate Alzheimer's disease from frontotemporal dementia?, J Alzheimers Dis, 36, 57, 10.3233/JAD-122293
Frisoni, 2007, The topography of grey matter involvement in early and late onset Alzheimer's disease, Brain, 130, 720, 10.1093/brain/awl377
Whitwell, 2012, Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study, Lancet Neurol, 11, 868, 10.1016/S1474-4422(12)70200-4
Giedd, 1995, Reliability of cerebral measures in repeated examinations with magnetic resonance imaging, Psychiatry Res, 61, 113, 10.1016/0925-4927(95)02593-M
den Heijer, 2010, A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline, Brain, 133, 1163, 10.1093/brain/awq048
Lo, 2011, Longitudinal change of biomarkers in cognitive decline, Arch Neurol, 68, 1257, 10.1001/archneurol.2011.123
Anchisi, 2005, Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease, Arch Neurol, 62, 1728, 10.1001/archneur.62.11.1728
Drzezga, 2003, Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study, Eur J Nucl Med Mol Imaging, 30, 1104, 10.1007/s00259-003-1194-1
Mosconi, 2005, Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD, Eur J Nucl Med Mol Imaging, 32, 486, 10.1007/s00259-005-1762-7
Alexander, 2002, Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies, Am J Psychiatry, 159, 738, 10.1176/appi.ajp.159.5.738
de Leon, 2001, Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET), Proc Natl Acad Sci USA, 98, 10966, 10.1073/pnas.191044198
Johnson, 2012, Brain imaging in Alzheimer disease, Cold Spring Harb Perspect Med, 2, a006213, 10.1101/cshperspect.a006213
Mosconi, 2009, FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease, Eur J Nucl Med Mol Imaging, 36, 811, 10.1007/s00259-008-1039-z
Caroli, 2012, Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison, J Nucl Med, 53, 592, 10.2967/jnumed.111.094946
Scholl, 2011, Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers, J Alzheimers Dis, 24, 495, 10.3233/JAD-2011-101563
Giovacchini, 2011, PET translates neurophysiology into images: A review to stimulate a network between neuroimaging and basic research, J Cell Physiol, 226, 948, 10.1002/jcp.22451
Rocher, 2003, Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons, Neuroimage, 20, 1894, 10.1016/j.neuroimage.2003.07.002
Bohnen, 2012, Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature, J Nucl Med, 53, 59, 10.2967/jnumed.111.096578
Lehmann, 2013, Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease, Brain, 136, 844, 10.1093/brain/aws327
Silverman, 2003, Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET, Mol Genet Metab, 80, 350, 10.1016/S1096-7192(03)00139-2
Kennedy, 1995, Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease, Neurosci Lett, 186, 17, 10.1016/0304-3940(95)11270-7
Reiman, 2004, Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia, Proc Natl Acad Sci USA, 101, 284, 10.1073/pnas.2635903100
Small, 2000, Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease, Proc Natl Acad Sci USA, 97, 6037, 10.1073/pnas.090106797
Foster, 2007, FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease, Brain, 130, 2616, 10.1093/brain/awm177
Mosconi, 2008, Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias, J Nucl Med, 49, 390, 10.2967/jnumed.107.045385
Rabinovici, 2008, Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia, Ann Neurol, 64, 388, 10.1002/ana.21451
Ewers, 2013, Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease, Neurology, 80, 1194, 10.1212/WNL.0b013e31828970c2
Garibotto, 2008, Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence, Neurology, 71, 1342, 10.1212/01.wnl.0000327670.62378.c0
Stern, 2012, Cognitive reserve in ageing and Alzheimer's disease, Lancet Neurol, 11, 1006, 10.1016/S1474-4422(12)70191-6
Lowe, 2013, Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI, Neurology, 80, 2130, 10.1212/WNL.0b013e318295d6cf
Stricker, 2011, Distinct profiles of brain and cognitive changes in the very old with Alzheimer disease, Neurology, 77, 713, 10.1212/WNL.0b013e31822b0004
Butters, 1996, Focal temporal lobe dysfunction in probable Alzheimer's disease predicts a slow rate of cognitive decline, Neurology, 46, 687, 10.1212/WNL.46.3.687
Cappa, 2001, Brain perfusion abnormalities in Alzheimer's disease: comparison between patients with focal temporal lobe dysfunction and patients with diffuse cognitive impairment, J Neurol Neurosurg Psychiatry, 70, 22, 10.1136/jnnp.70.1.22
Marra, 2012, Probable Alzheimer's disease patients presenting as “focal temporal lobe dysfunction” show a slow rate of cognitive decline, J Int Neuropsychol Soc, 18, 144, 10.1017/S1355617711001287
Mattsson, 2012, Age and diagnostic performance of Alzheimer disease CSF biomarkers, Neurology, 78, 468, 10.1212/WNL.0b013e3182477eed
Holland, 2012, Rates of decline in Alzheimer disease decrease with age, PLoS One, 7, e42325, 10.1371/journal.pone.0042325
Dartigues, 2011, Risk factors for Alzheimer disease: aging beyond age?, Neurology, 77, 206, 10.1212/WNL.0b013e31822550af
Chiu, 2007, Relevance of outcome measures in different cultural groups--does one size fit all?, Int Psychogeriatr, 19, 457, 10.1017/S1041610207004838
Caramelli, 2011, The Pieta study: epidemiological investigation on successful brain aging in Caete (MG), Brazil. Methods and baseline cohort characteristics, Arq Neuropsiquiatr, 69, 579, 10.1590/S0004-282X2011000500002
Karlawish, 2011, Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease, Neurology, 77, 1487, 10.1212/WNL.0b013e318232ac1a